Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 8 of 8 entries
Sorted by: Best Match Show Resources per page
Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome: lipoproteins in alcoholic hepatitis.

Journal of clinical lipidology

Mathur K, Vilar-Gomez E, Connelly MA, He H, Sanyal AJ, Chalasani N, Jiang ZG.
PMID: 34756674
J Clin Lipidol. 2021 Nov-Dec;15(6):805-813. doi: 10.1016/j.jacl.2021.10.002. Epub 2021 Oct 20.

BACKGROUND: Alcohol-associated liver disease (ALD) and alcoholic hepatitis (AH) significantly impact the liver, an organ central to the lipid and lipoprotein metabolism.OBJECTIVE: To define changes in the lipid and lipoprotein profiles in subjects with alcoholic hepatitis (AH) versus heavy...

Cite
Mathur K, Vilar-Gomez E, Connelly MA, et al. Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome: lipoproteins in alcoholic hepatitis. J Clin Lipidol. 2021;15(6):805-813doi: 10.1016/j.jacl.2021.10.002.
Mathur, K., Vilar-Gomez, E., Connelly, M. A., He, H., Sanyal, A. J., Chalasani, N., & Jiang, Z. G. (2021). Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome: lipoproteins in alcoholic hepatitis. Journal of clinical lipidology, 15(6), 805-813. https://doi.org/10.1016/j.jacl.2021.10.002
Mathur, Karan, et al. "Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome: lipoproteins in alcoholic hepatitis." Journal of clinical lipidology vol. 15,6 (2021): 805-813. doi: https://doi.org/10.1016/j.jacl.2021.10.002
Mathur K, Vilar-Gomez E, Connelly MA, He H, Sanyal AJ, Chalasani N, Jiang ZG. Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome: lipoproteins in alcoholic hepatitis. J Clin Lipidol. 2021 Nov-Dec;15(6):805-813. doi: 10.1016/j.jacl.2021.10.002. Epub 2021 Oct 20. PMID: 34756674; PMCID: PMC8688310.
Copy Download .nbib Format: NLM
Adenosine deaminase 2 produced by infiltrative monocytes promotes liver fibrosis in nonalcoholic fatty liver disease.

Cell reports

Tiwari-Heckler S, Yee EU, Yalcin Y, Park J, Nguyen DT, Gao W, Csizmadia E, Afdhal N, Mukamal KJ, Robson SC, Lai M, Schwartz RE, Jiang ZG.
PMID: 34706243
Cell Rep. 2021 Oct 26;37(4):109897. doi: 10.1016/j.celrep.2021.109897.

Elevated circulating activity of adenosine deaminase 2 (ADA2) is associated with liver fibrosis in nonalcoholic fatty liver disease (NAFLD). In the liver of NAFLD patients, ADA2-positive portal macrophages are significantly associated with the degree of liver fibrosis. These liver...

Cite
Tiwari-Heckler S, Yee EU, Yalcin Y, et al. Adenosine deaminase 2 produced by infiltrative monocytes promotes liver fibrosis in nonalcoholic fatty liver disease. Cell Rep. 2021;37(4):109897doi: 10.1016/j.celrep.2021.109897.
Tiwari-Heckler, S., Yee, E. U., Yalcin, Y., Park, J., Nguyen, D. T., Gao, W., Csizmadia, E., Afdhal, N., Mukamal, K. J., Robson, S. C., Lai, M., Schwartz, R. E., & Jiang, Z. G. (2021). Adenosine deaminase 2 produced by infiltrative monocytes promotes liver fibrosis in nonalcoholic fatty liver disease. Cell reports, 37(4), 109897. https://doi.org/10.1016/j.celrep.2021.109897
Tiwari-Heckler, Shilpa, et al. "Adenosine deaminase 2 produced by infiltrative monocytes promotes liver fibrosis in nonalcoholic fatty liver disease." Cell reports vol. 37,4 (2021): 109897. doi: https://doi.org/10.1016/j.celrep.2021.109897
Tiwari-Heckler S, Yee EU, Yalcin Y, Park J, Nguyen DT, Gao W, Csizmadia E, Afdhal N, Mukamal KJ, Robson SC, Lai M, Schwartz RE, Jiang ZG. Adenosine deaminase 2 produced by infiltrative monocytes promotes liver fibrosis in nonalcoholic fatty liver disease. Cell Rep. 2021 Oct 26;37(4):109897. doi: 10.1016/j.celrep.2021.109897. PMID: 34706243; PMCID: PMC8606247.
Copy Download .nbib Format: NLM
Severe Hepatic Steatosis by Controlled Attenuation Parameter Predicts Quality of Life Independent of Fibrosis.

Digestive diseases and sciences

Trivedi HD, Niezen S, Jiang ZG, Tapper EB.
PMID: 34417922
Dig Dis Sci. 2021 Aug 21; doi: 10.1007/s10620-021-07228-3. Epub 2021 Aug 21.

BACKGROUND & AIM: Liver fibrosis is associated with poor patient-reported outcomes (PROs), but the impact of steatosis is unknown. We aimed to evaluate the impact of steatosis on PROs independent of liver fibrosis.METHODS: We evaluated the impact of steatosis,...

Cite
Trivedi HD, Niezen S, Jiang ZG, et al. Severe Hepatic Steatosis by Controlled Attenuation Parameter Predicts Quality of Life Independent of Fibrosis. Dig Dis Sci. 2021;doi: 10.1007/s10620-021-07228-3.
Trivedi, H. D., Niezen, S., Jiang, Z. G., & Tapper, E. B. (2021). Severe Hepatic Steatosis by Controlled Attenuation Parameter Predicts Quality of Life Independent of Fibrosis. Digestive diseases and sciences, . https://doi.org/10.1007/s10620-021-07228-3
Trivedi, Hirsh D, et al. "Severe Hepatic Steatosis by Controlled Attenuation Parameter Predicts Quality of Life Independent of Fibrosis." Digestive diseases and sciences vol. (2021). doi: https://doi.org/10.1007/s10620-021-07228-3
Trivedi HD, Niezen S, Jiang ZG, Tapper EB. Severe Hepatic Steatosis by Controlled Attenuation Parameter Predicts Quality of Life Independent of Fibrosis. Dig Dis Sci. 2021 Aug 21; doi: 10.1007/s10620-021-07228-3. Epub 2021 Aug 21. PMID: 34417922.
Copy Download .nbib Format: NLM
Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome: lipoproteins in alcoholic hepatitis.

Journal of clinical lipidology

Mathur K, Vilar-Gomez E, Connelly MA, He H, Sanyal AJ, Chalasani N, Jiang ZG.
PMID: 34756674
J Clin Lipidol. 2021 Nov-Dec;15(6):805-813. doi: 10.1016/j.jacl.2021.10.002. Epub 2021 Oct 20.

BACKGROUND: Alcohol-associated liver disease (ALD) and alcoholic hepatitis (AH) significantly impact the liver, an organ central to the lipid and lipoprotein metabolism.OBJECTIVE: To define changes in the lipid and lipoprotein profiles in subjects with alcoholic hepatitis (AH) versus heavy...

Cite
Mathur K, Vilar-Gomez E, Connelly MA, et al. Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome: lipoproteins in alcoholic hepatitis. J Clin Lipidol. 2021;15(6):805-813doi: 10.1016/j.jacl.2021.10.002.
Mathur, K., Vilar-Gomez, E., Connelly, M. A., He, H., Sanyal, A. J., Chalasani, N., & Jiang, Z. G. (2021). Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome: lipoproteins in alcoholic hepatitis. Journal of clinical lipidology, 15(6), 805-813. https://doi.org/10.1016/j.jacl.2021.10.002
Mathur, Karan, et al. "Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome: lipoproteins in alcoholic hepatitis." Journal of clinical lipidology vol. 15,6 (2021): 805-813. doi: https://doi.org/10.1016/j.jacl.2021.10.002
Mathur K, Vilar-Gomez E, Connelly MA, He H, Sanyal AJ, Chalasani N, Jiang ZG. Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome: lipoproteins in alcoholic hepatitis. J Clin Lipidol. 2021 Nov-Dec;15(6):805-813. doi: 10.1016/j.jacl.2021.10.002. Epub 2021 Oct 20. PMID: 34756674; PMCID: PMC8688310.
Copy Download .nbib Format: NLM
Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome: lipoproteins in alcoholic hepatitis.

Journal of clinical lipidology

Mathur K, Vilar-Gomez E, Connelly MA, He H, Sanyal AJ, Chalasani N, Jiang ZG.
PMID: 34756674
J Clin Lipidol. 2021 Nov-Dec;15(6):805-813. doi: 10.1016/j.jacl.2021.10.002. Epub 2021 Oct 20.

BACKGROUND: Alcohol-associated liver disease (ALD) and alcoholic hepatitis (AH) significantly impact the liver, an organ central to the lipid and lipoprotein metabolism.OBJECTIVE: To define changes in the lipid and lipoprotein profiles in subjects with alcoholic hepatitis (AH) versus heavy...

Cite
Mathur K, Vilar-Gomez E, Connelly MA, et al. Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome: lipoproteins in alcoholic hepatitis. J Clin Lipidol. 2021;15(6):805-813doi: 10.1016/j.jacl.2021.10.002.
Mathur, K., Vilar-Gomez, E., Connelly, M. A., He, H., Sanyal, A. J., Chalasani, N., & Jiang, Z. G. (2021). Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome: lipoproteins in alcoholic hepatitis. Journal of clinical lipidology, 15(6), 805-813. https://doi.org/10.1016/j.jacl.2021.10.002
Mathur, Karan, et al. "Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome: lipoproteins in alcoholic hepatitis." Journal of clinical lipidology vol. 15,6 (2021): 805-813. doi: https://doi.org/10.1016/j.jacl.2021.10.002
Mathur K, Vilar-Gomez E, Connelly MA, He H, Sanyal AJ, Chalasani N, Jiang ZG. Circulating high density lipoprotein distinguishes alcoholic hepatitis from heavy drinkers and predicts 90-day outcome: lipoproteins in alcoholic hepatitis. J Clin Lipidol. 2021 Nov-Dec;15(6):805-813. doi: 10.1016/j.jacl.2021.10.002. Epub 2021 Oct 20. PMID: 34756674.
Copy Download .nbib Format: NLM
Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis.

Hepatology (Baltimore, Md.)

Hu K, Perez-Matos MC, Argemi J, Vilar-Gomez E, Shalaurova I, Bullitt E, Landeen L, Sugahara G, Deng H, Mathur K, Tran S, Cai H, He H, Yalcin Y, Vieira Barbosa J, Ventura-Cots M, Marx K, Gad AP, Niezen S, Izunza Barba S, Ang LH, Popov YV, Fricker Z, Lai M, Curry M, Afdhal N, Szabo G, Mukamal KJ, Sanyal AJ, Otvos JD, Malik R, Saito T, Connelly MA, Chalasani NP, Bataller R, Jiang ZG.
PMID: 34662439
Hepatology. 2021 Oct 18; doi: 10.1002/hep.32203. Epub 2021 Oct 18.

BACKGROUND AND AIMS: Lipoprotein Z (LP-Z) is an abnormal free cholesterol (FC)-enriched LDL-like particle discovered from patients with cholestatic liver disease. This study aims to define the diagnostic value of LP-Z in alcohol-associated hepatitis (AH) and interrogate the biology...

Cite
Hu K, Perez-Matos MC, Argemi J, et al. Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis. Hepatology. 2021;doi: 10.1002/hep.32203.
Hu, K., Perez-Matos, M. C., Argemi, J., Vilar-Gomez, E., Shalaurova, I., Bullitt, E., Landeen, L., Sugahara, G., Deng, H., Mathur, K., Tran, S., Cai, H., He, H., Yalcin, Y., Vieira Barbosa, J., Ventura-Cots, M., Marx, K., Gad, A. P., Niezen, S., Izunza Barba, S., Ang, L. H., Popov, Y. V., Fricker, Z., Lai, M., Curry, M., Afdhal, N., Szabo, G., Mukamal, K. J., Sanyal, A. J., Otvos, J. D., Malik, R., Saito, T., Connelly, M. A., Chalasani, N. P., Bataller, R., & Jiang, Z. G. (2021). Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis. Hepatology (Baltimore, Md.), . https://doi.org/10.1002/hep.32203
Hu, Kunpeng, et al. "Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis." Hepatology (Baltimore, Md.) vol. (2021). doi: https://doi.org/10.1002/hep.32203
Hu K, Perez-Matos MC, Argemi J, Vilar-Gomez E, Shalaurova I, Bullitt E, Landeen L, Sugahara G, Deng H, Mathur K, Tran S, Cai H, He H, Yalcin Y, Vieira Barbosa J, Ventura-Cots M, Marx K, Gad AP, Niezen S, Izunza Barba S, Ang LH, Popov YV, Fricker Z, Lai M, Curry M, Afdhal N, Szabo G, Mukamal KJ, Sanyal AJ, Otvos JD, Malik R, Saito T, Connelly MA, Chalasani NP, Bataller R, Jiang ZG. Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis. Hepatology. 2021 Oct 18; doi: 10.1002/hep.32203. Epub 2021 Oct 18. PMID: 34662439.
Copy Download .nbib Format: NLM
Coffee Consumption Is Associated With Lower Liver Stiffness: A Nationally Representative Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Niezen S, Mehta M, Jiang ZG, Tapper EB.
PMID: 34626832
Clin Gastroenterol Hepatol. 2021 Oct 06; doi: 10.1016/j.cgh.2021.09.042. Epub 2021 Oct 06.

BACKGROUND & AIMS: Coffee is associated with a reduced risk of liver disease. This association is limited by important sources of confounding such as recall bias, healthy user bias, and indirect measures of liver outcomes or health. We aimed...

Cite
Niezen S, Mehta M, Jiang ZG, et al. Coffee Consumption Is Associated With Lower Liver Stiffness: A Nationally Representative Study. Clin Gastroenterol Hepatol. 2021;doi: 10.1016/j.cgh.2021.09.042.
Niezen, S., Mehta, M., Jiang, Z. G., & Tapper, E. B. (2021). Coffee Consumption Is Associated With Lower Liver Stiffness: A Nationally Representative Study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, . https://doi.org/10.1016/j.cgh.2021.09.042
Niezen, Sebastian, et al. "Coffee Consumption Is Associated With Lower Liver Stiffness: A Nationally Representative Study." Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association vol. (2021). doi: https://doi.org/10.1016/j.cgh.2021.09.042
Niezen S, Mehta M, Jiang ZG, Tapper EB. Coffee Consumption Is Associated With Lower Liver Stiffness: A Nationally Representative Study. Clin Gastroenterol Hepatol. 2021 Oct 06; doi: 10.1016/j.cgh.2021.09.042. Epub 2021 Oct 06. PMID: 34626832.
Copy Download .nbib Format: NLM
Prevalence of High Liver Stiffness and a Screening Strategy Using the SODA-2B Score Among US Adults.

Hepatology communications

Niezen S, Tapper EB, Trivedi H, Lai M, Curry MP, Mukamal KJ, Jiang ZG.
PMID: 34697916
Hepatol Commun. 2021 Oct 25; doi: 10.1002/hep4.1837. Epub 2021 Oct 25.

Cirrhosis, a rising cause of death in the United States, has an extended preclinical phase characterized by progressive liver fibrosis. Despite the developments in noninvasive fibrosis measurement, there is no recommended screening, in part due to an incomplete understanding...

Cite
Niezen S, Tapper EB, Trivedi H, et al. Prevalence of High Liver Stiffness and a Screening Strategy Using the SODA-2B Score Among US Adults. Hepatol Commun. 2021;doi: 10.1002/hep4.1837.
Niezen, S., Tapper, E. B., Trivedi, H., Lai, M., Curry, M. P., Mukamal, K. J., & Jiang, Z. G. (2021). Prevalence of High Liver Stiffness and a Screening Strategy Using the SODA-2B Score Among US Adults. Hepatology communications, . https://doi.org/10.1002/hep4.1837
Niezen, Sebastian, et al. "Prevalence of High Liver Stiffness and a Screening Strategy Using the SODA-2B Score Among US Adults." Hepatology communications vol. (2021). doi: https://doi.org/10.1002/hep4.1837
Niezen S, Tapper EB, Trivedi H, Lai M, Curry MP, Mukamal KJ, Jiang ZG. Prevalence of High Liver Stiffness and a Screening Strategy Using the SODA-2B Score Among US Adults. Hepatol Commun. 2021 Oct 25; doi: 10.1002/hep4.1837. Epub 2021 Oct 25. PMID: 34697916.
Copy Download .nbib Format: NLM
Showing 1 to 8 of 8 entries